DekaBank Deutsche Girozentrale Sells 115,287 Shares of GT Biopharma, Inc. (NASDAQ:GTBP)

DekaBank Deutsche Girozentrale decreased its holdings in shares of GT Biopharma, Inc. (NASDAQ:GTBP) by 10.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 978,358 shares of the company’s stock after selling 115,287 shares during the period. DekaBank Deutsche Girozentrale owned approximately 69.04% of GT Biopharma worth $2,769,000 as of its most recent SEC filing.

GT Biopharma Price Performance

NASDAQ:GTBP opened at $2.18 on Thursday. GT Biopharma, Inc. has a 52-week low of $1.95 and a 52-week high of $10.66. The stock has a fifty day moving average of $2.37 and a 200 day moving average of $3.24.

GT Biopharma (NASDAQ:GTBP) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($2.24) earnings per share (EPS) for the quarter.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.